Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Makes Further Inroads In Oncology As Humira Loss Looms

Executive Summary

New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.

Advertisement

Related Content

Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy
Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More
AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Venclyxto Gets EU Nod – But Won't Be A Humira Replacement For AbbVie Yet
Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Venclexta Win Broadens AbbVie/Genentech CLL Positions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel